<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined the effects of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> on urinary podocyte excretion </plain></SENT>
<SENT sid="1" pm="."><plain>Thirteen patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> receiving 2.5mg of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> were recruited and the medication was switched to 10mg of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> for a 24-week period </plain></SENT>
<SENT sid="2" pm="."><plain>With the switch to <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>, the urinary excretion of podocytes was significantly reduced </plain></SENT>
</text></document>